Keyphrases
Clinical Activity
100%
Safety Activity
100%
Tolerability
100%
Metastatic Non-small Cell Lung Cancer
100%
Pembrolizumab
100%
Selinexor
100%
Programmed Death-ligand 1 (PD-L1)
42%
Nuclear Export Signal
42%
Efficacy Data
28%
Clinical Safety
28%
Progression-free Survival
28%
Toxic Effects
28%
Disease Control Rate
28%
Immunomodulatory Activity
28%
Safety Efficacy
28%
Nuclear Export Inhibitors
28%
Early Efficacy
28%
Tumor Protein p53 (TP53)
14%
Antitumor Activity
14%
Systemic Therapy
14%
Overexpression
14%
Response to Treatment
14%
Median Overall Survival
14%
Safety Data
14%
Adverse Events
14%
Lung Cancer
14%
Overall Response Rate
14%
Survival Duration
14%
Objective Tumor Response
14%
Tumor Response Rate
14%
Trial Registration
14%
Therapy-related
14%
Cell Cycle Regulators
14%
Driver mutations
14%
Two-line
14%
Suppressor Cells
14%
Tumor Suppress
14%
Prior Exposure
14%
Selective Suppression
14%
Immune Checkpoint Inhibitors
14%
Plain Language Summary
14%
Investigator-initiated Studies
14%
Pharmacology, Toxicology and Pharmaceutical Science
Lung Cancer
100%
Tolerability
100%
Pembrolizumab
100%
Selinexor
100%
Programmed Death 1 Ligand 1
42%
Diseases
28%
Neoplasm
28%
Progression Free Survival
28%
Toxicity
28%
Tumor Suppressor Protein
14%
Antitumor Activity
14%
Overall Survival
14%
Adverse Event
14%
Immune Checkpoint Inhibitor
14%